tolazamide 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |

Stem definitionDrug idCAS RN
antihyperglycaemics 2694 1156-19-0

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • tolazamide
  • norglycin
  • tolanase
  • tolinase
A sulphonylurea hypoglycemic agent with actions and uses similar to those of CHLORPROPAMIDE.
  • Molecular weight: 311.40
  • Formula: C14H21N3O3S
  • CLOGP: 1.34
  • LIPINSKI: 0
  • HAC: 6
  • HDO: 2
  • TPSA: 78.51
  • ALOGS: -3.01
  • ROTB: 2
  • Status: OFM
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
0.50 g O

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 2 Benet LZ, Broccatelli F, Oprea TI
S (Water solubility) 0.28 mg/mL Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 53.63 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD

Predicted pharmacokinetic/toxicological properties (PK-AZ):

PropertyDescriptionValueUnitConfidenceSimilarity
azlogd74 LogD at pH 7.4 0.460 High 1
caco2-efflux Caco-2 efflux ratio (BA/AB) 0.940 High 1
caco2-intrinsic-papp Caco-2 intrinsic apparent permeability 55.719 10^-6 cm/s High 1
dh-clint Dog hepatocyte intrinsic clearance 3.459 uL/min/10^6 cells High 1
dppb Dog plasma protein binding (% unbound) 16.250 % High 1
fcs-ppb Fetal calf serum protein binding (% unbound) 17.650 % High 1
herg hERG pIC50 4.600 pIC50 High 1
hh-clint Human hepatocyte intrinsic clearance 1.483 uL/min/10^6 cells High 1
hlm-clint Human liver microsomal intrinsic clearance 3.097 uL/min/mg protein High 1
hppb Human plasma protein binding (% unbound) 8.590 % High 1
kinase-safety-class ACVR2A,ACVR2B,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DYRK1B,EIF2AK3,ERBB2,GRK2,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PRKDC,SIK2,SIK3,STK33,TEK 23
kinase-selectivity-class AXL,EIF2AK3,GRK2,PDK4,TTK 5
mdck-mdr1-bcrp-efflux MDCK-MDR1-BCRP efflux ratio 3.540 Moderate 0.70
mdck-mdr1-efflux MDCK-MDR1 efflux ratio 3.412 High 1
mh-clint Mouse hepatocyte intrinsic clearance 12.474 High 1
mppb Mouse plasma protein binding (% unbound) 20.940 High 1
nih-mdck-mdr1-efflux NIH MDCK-MDR1 efflux ratio 3.540 High 1
pfas-class PFAS structural alert (1 = True, 0 = False) 0
pppb Pig plasma protein binding (% unbound) 19.710 % High 1
rat-kpuu-brain Rat brain Kpuu 0.154 % Moderate 0.70
rh-clint Rat hepatocyte intrinsic clearance 3.917 uL/min/10^6 cells High 1
rh-fuinc Rat hepatocyte fraction unbound in incubation 86.020 % High 1
rppb Rat plasma protein binding (% unbound) 6.650 % High 1
solubility-dd Solubility at pH 7.4 in DMSO 946.237 uM High 1

Approvals:

DateAgencyCompanyOrphan
July 18, 1966 FDA

FDA Adverse Event Reporting System (Female)

None

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

None

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC A10BB05 ALIMENTARY TRACT AND METABOLISM
DRUGS USED IN DIABETES
BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Sulfonylureas
FDA CS M0020795 Sulfonylurea Compounds
MeSH PA D007004 Hypoglycemic Agents
FDA EPC N0000175608 Sulfonylurea
CHEBI has role CHEBI:35526 hypoglycemic agent
CHEBI has role CHEBI:50509 potassium channel blocker

Related Drugs by ATC class:

A10BB Sulfonylureas 12 drugs
acetohexamidecarbutamidechlorpropamideglibenclamideglibornuridegliclazideglimepirideglipizidegliquidoneglisoxepidemetahexamidetolbutamide

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Diabetes mellitus type 2 indication 44054006 DOID:9352
Alcoholism contraindication 7200002
Asthenia contraindication 13791008
Uremia contraindication 44730006 DOID:4676
Acidosis contraindication 51387008
Hepatic porphyria contraindication 55056006 DOID:3133
Hypopituitarism contraindication 74728003 DOID:9406
Kidney disease contraindication 90708001 DOID:557
Disease of liver contraindication 235856003 DOID:409
Hypoglycemic disorder contraindication 237630007
Primary adrenocortical insufficiency contraindication 373662000
Surgical procedure contraindication 387713003
Traumatic injury contraindication 417746004
Fever greater than 100.4 Fahrenheit contraindication 426000000
Prolonged-Severe Nausea and Vomiting contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 5.97 acidic
pKa2 3.54 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Sulfonylurea receptor 1, Kir6.2 Ion channel BLOCKER CHEMBL CHEMBL
Arachidonate 15-lipoxygenase Enzyme IC50 5.29 DRUG MATRIX

External reference:

IDSource
4017829 VUID
N0000146187 NUI
D00379 KEGG_DRUG
4017829 VANDF
C0040372 UMLSCUI
CHEBI:9613 CHEBI
CHEMBL817 ChEMBL_ID
DB00839 DRUGBANK_ID
D014042 MESH_DESCRIPTOR_UI
5503 PUBCHEM_CID
6847 IUPHAR_LIGAND_ID
1296 INN_ID
9LT1BRO48Q UNII
10633 RXNORM
1119 MMSL
1138 MMSL
5593 MMSL
d00393 MMSL
000911 NDDF
34393009 SNOMEDCT_US
387186009 SNOMEDCT_US
9LT1BRO48Q INXIGHT DRUGS

Pharmaceutical products:

None